The development of our clinical algorithm can facilitate shared decision-making for clinicians and patients by providing information from the personalized risk model—for example, charts showing the cumulative risks of high-grade PrCa and PrCa death for patients with different PSA levels and genetic risk (Figure S1). This evidence concerns the gene KLK3 and pure red-cell aplasia.